2. Aires thérapeutique
  3. Urogenital Disease
  4. Female Reproductive System Disease

Female Reproductive System Disease

Female reproductive system diseases encompass a range of conditions affecting the vagina, cervix, uterus, ovaries, fallopian tubes, and breasts, leading to symptoms such as abnormal vaginal discharge, pelvic pain, menstrual irregularities, infertility, and in some cases, malignant transformation. Common disorders include vaginitis, pelvic inflammatory disease (PID), endometriosis, polycystic ovary syndrome (PCOS), and gynecological cancers such as cervical, ovarian, endometrial, and breast cancer. These conditions arise from diverse etiologies including bacterial infections, hormonal imbalances, genetic predispositions, and aberrant cell growth. Abnormalities in key genes like MIR199A1 and dysregulation of microRNA pathways involved in DNA damage response and immune cell interactions contribute to disease pathogenesis. Rare conditions such as abdominal pregnancy further illustrate the complexity of reproductive health. Affected tissues include the cervix and uterus, with clinical manifestations often involving leukorrhea, mastodynia, and genital itching. Treatments may involve antibiotics for infections, hormonal therapies for PCOS and endometriosis, and targeted interventions for malignancies, while drugs like alprazolam and propofol are noted in associated clinical contexts.

 

Female Reproductive System Disease (42):

Cat. No. Nom du produit CAS No. Pureté Chemical Structure
  • HY-136436
    Ternidazole hydrochloride 70028-95-4 99.29%
    Ternidazole hydrochloride is a nitroimidazole Antibiotic with anti-pathogenic microbial activity. Ternidazole hydrochloride kills and inhibits the visible growth of Clostridium perfringens type A in vitro. Ternidazole hydrochloride helps improve the therapeutic efficacy against bacterial vaginosis, candidal vaginitis and mixed vaginitis. Ternidazole hydrochloride effectively alleviates chronic alcoholism. Ternidazole hydrochloride can be used in research related to vaginitis, pathogenic microbial infections and chronic alcoholism.
    Ternidazole hydrochloride
  • HY-117878
    ML345 1632125-79-1 99.37%
    ML345 is a potent and selective inhibitor of insulin-degrading enzyme (IDE) and NLRP3, with an IC50 of 188 nM against IDE. ML345 targets the Cys819 residue of IDE to inhibit IDE. ML345 selectively binds to NLRP3 in a non-covalent manner. ML345 inhibits inflammatory cytokines (IL-1β, IL-6) and exhibits potent anti-inflammatory activity. ML345 exerts a protective effect against miscarriage.
    ML345
  • HY-164238
    LysoPC(18:3) 62512-91-8
    LysoPC (18:3) is a type of lysophospholipid metabolite with biomarker properties. LysoPC (18:3) stably exists in human follicular fluid, and its abundance dynamically changes with age, synchronously regulating the body's lipid metabolism process, follicular development process and oocyte maturation process. The down-regulation of LysoPC (18:3) content is associated with breast cancer lesions and follicular aging changes accompanied by in vitro fertilization in elderly women. LysoPC (18:3) can be used in studies related to breast cancer and infertility in elderly women.
    LysoPC(18:3)
  • HY-Y1217
    1-Cyclohexanol 108-93-0 99.94%
    1-Cyclohexanol (Hydroxycyclohexane; NSC 5471) is an orally active Cramer Class I flavor ingredient that can be used in fragrances. 1-Cyclohexanol has a wide margin of safety and is environmentally friendly.
    1-Cyclohexanol
  • HY-B1403
    Dienestrol 84-17-3 98.08%
    Dienestrol is an orally active nonsteroidal estrogen. Dienestrol prevents the formation of implantation swellings in the uterus by inhibiting ovum discharge.
    Dienestrol
  • HY-179528
    DIM-3,5-Cl2 2595179-74-9 99.18%
    DIM-3,5-Cl2 is an inverse NR4A1/NR4A2 agonist with KD values of 7.7 μM and 12.0 μM for NR4A1 and NR4A2, respectively. DIM-3,5-Cl2 acts as an inverse agonist to downregulate pro-oncogenic and proendometriotic gene products, and as an agonist to enhance NR4A1/2/Sp1/Sp4-mediated CD71 transactivation. DIM-3,5-Cl2 induces ferroptosis via ROS formation, lipoperoxidation, MDA production, and reduced GPX4, SLC7A11 expression. DIM-3,5-Cl2 induces apoptosis via PARP and caspase-3 cleavage, reduced BCL-2 expression, and inhibits cancer cell viability. DIM-3,5-Cl2 can be used for the research of triple negative breast cancer, endometriosis, and colorectal cancer.
    DIM-3,5-Cl2
  • HY-P3343
    hFSH-β-(33-53) 142154-55-0
    hFSH-β-(33-53) is a polypeptide corresponding to residues 33-53 of hFSH-β, and also a follicle-stimulating hormone (FSH) antagonist. hFSH-β-(33-53) stimulates basal estradiol synthesis in cells. hFSH-β-(33-53) prolongs vaginal estrus in mice with normal estrous cycles.
    hFSH-β-(33-53)
  • HY-165456
    AGN-190851 134892-42-5
    AGN-190851 is a potent and selective agonist of α2-adrenergic receptor (α2 adrenoceptor). AGN-190851 induces dose-dependent water diuresis in rats, and inhibits vasopressin V2 receptor in a species-dependent manner in vitro, thereby suppressing cAMP production. AGN-190851 enhances the contraction of porcine myometrium. AGN 190851 can be used in studies on renal diuretic mechanisms, pharmacology of α2-adrenergic receptor subtypes, and parturition.
    AGN-190851
  • HY-116568
    Prothioconazole 178928-70-6 99.52%
    Prothioconazole is an orally active broad-spectrum fungicide. Prothioconazole weakly inhibits CaCYP51 activity in Candida albicans, with an apparent IC50 of approximately 120 μM. Prothioconazole disrupts Microtubule stability by reducing the acetylation level of α-tubulin. Prothioconazole induces Mitochondrial dysfunction, oxidative stress, DNA damage, and Apoptosis. Prothioconazole accumulates 14-methylated sterols and depletes ergosterol in cells, culture media, plants, and animals. Prothioconazole interferes with pyruvate metabolism and glycolysis/gluconeogenesis processes in mouse liver, downregulates Fasn mRNA expression, and induces hepatotoxicity and renal metabolic disorders. Prothioconazole reduces the fertility of female mice. Prothioconazole inhibits body weight gain and increases liver/kidney indices in mice. Prothioconazole can be used in studies related to candidiasis.
    Prothioconazole
  • HY-17522
    Meptyldinocap 131-72-6 99.91%
    Meptyldinocap (2,4-DNOPC) is a fungicide and cytotoxic agent that acts against powdery mildew. Meptyldinocap upregulates the phosphorylation levels of ERK1/2, JNK and p38. Meptyldinocap induces apoptosis and endoplasmic reticulum stress, disrupts calcium homeostasis, inhibits cell proliferation and migration, downregulates the expression of proliferation- and pregnancy-related genes, and triggers mitochondrial dysfunction. Meptyldinocap can be used in studies related to powdery mildew and implantation failure.
    Meptyldinocap
  • HY-136436A
    Ternidazole 1077-93-6 99.11%
    Ternidazole is a nitroimidazole Antibiotic with anti-pathogenic microbial activity. Ternidazole kills and inhibits the visible growth of Clostridium perfringens type A in vitro. Ternidazole helps improve the therapeutic efficacy against bacterial vaginosis, candidal vaginitis and mixed vaginitis. Ternidazole effectively alleviates chronic alcoholism. Ternidazole can be used in research related to vaginitis, pathogenic microbial infections and chronic alcoholism.
    Ternidazole
  • HY-W587839
    4,8-Dioxa-3H-perfluorononanoic acid 919005-14-4
    4,8-Dioxa-3H-perfluorononanoic acid is an ether-substituted polyfluoroalkyl compound and also a ligand of human pregnane X receptor (hPXR), which binds to the ligand-binding domain of hPXR. 4,8-Dioxa-3H-perfluorononanoic acid targets Arg-410, Lys-210, Lys-226, Met-323 and His-327 residues. Its binding process relies on long-range electrostatic interactions, and no significant hydrogen bonds form with hPXR residues. 4,8-Dioxa-3H-perfluorononanoic acid is used as a substitute for PFOA in Germany. 4,8-Dioxa-3H-perfluorononanoic acid is detectable in environmental matrices such as river water near fluoride production plants, accumulates in organisms including grass, deer liver and locusts, and is present in plasma samples of populations in southern Germany.
    4,8-Dioxa-3H-perfluorononanoic acid
  • HY-156701
    BAY-1128688 1428988-21-9
    BAY-1128688 is a potent, orally active and selective AKR1C3 inhibitor with IC50 < 2 nM. BAY-1128688 shows high selectivity over related AKR1C enzymes (1C1, 1C2, 1C4) and AKR1D1. BAY-1128688 exhibits no relevant activity at major nuclear hormone receptors. BAY-1128688 reduces endometriotic lesions in the marmoset monkey endometriosis model. BAY-1128688 can be used for endometriosis research.
    BAY-1128688
  • HY-160645
    P2X4 antagonist-1 2055601-42-6 99.89%
    P2X4 antagonist-1 is a P2X4 receptor antagonist with an IC50 of 15 nM. P2X4 antagonist-1 inhibits ATP (HY-B2176)-induced calcium influx. P2X4 antagonist-1 can be used for the research of pain syndromes, endometriosis, cancer.
    P2X4 antagonist-1
  • HY-Y1217S1
    1-Cyclohexanol-d11 93131-17-0
    1-Cyclohexanol11 (Hydroxycyclohexane11; NSC 5471111) is the deuterium labeled 1-Cyclohexanol (HY-Y1217). 1-Cyclohexanol is an orally active Cramer Class I flavor ingredient that can be used in fragrances. 1-Cyclohexanol has a wide margin of safety and is environmentally friendly.
    1-Cyclohexanol-d<sub>11</sub>
  • HY-136436S
    Ternidazole-d6 hydrochloride 1346599-62-9
    Ternidazole-d6 hydrochloride is the deuterium labeled Ternidazole hydrochloride (HY-136436). Ternidazole hydrochloride is a nitroimidazole Antibiotic with anti-pathogenic microbial activity. Ternidazole hydrochloride kills and inhibits the visible growth of Clostridium perfringens type A in vitro. Ternidazole hydrochloride helps improve the therapeutic efficacy against bacterial vaginosis, candidal vaginitis and mixed vaginitis. Ternidazole hydrochloride effectively alleviates chronic alcoholism. Ternidazole hydrochloride can be used in research related to vaginitis, pathogenic microbial infections and chronic alcoholism.
    Ternidazole-d<sub>6</sub> hydrochloride
  • HY-184012
    BAY-163
    BAY-163 is a tertiary urea derivative and inactive negative control probe for BAY-439 (HY-178123). BAY-163 does not inhibit phospholipase A2 group V (PLA2-G5) activity in immune cells. BAY-163 can be used for research on endometriosis.
    BAY-163
  • HY-181443
    15(S)-15-Methyl Prostaglandin F2α ethyl amide
    15(S)-15-Methyl Prostaglandin F2α ethyl amide (15-Methyl Prostaglandin F2α ethyl amide) is a synthetic Prostaglandin F2α (HY-12956) analogue that stimulates uterine contractions. 15(S)-15-Methyl Prostaglandin F2α ethyl amide can be used for the research of second-trimester pregnancy loss.
    15(S)-15-Methyl Prostaglandin F2α ethyl amide
  • HY-182421
    GPR54 antagonist-1 925924-27-2
    GPR54 antagonist‑1 is a GPR54 antagonist with IC50 values of 3.6 nM and 15 nM against human and rat GPR54, respectively. GPR54 antagonist‑1 shows blood‑brain barrier penetration. GPR54 antagonist‑1 blocks the function of human and rat GPR54 receptors. GPR54 antagonist‑1 suppresses plasma luteinizing hormone levels in castrated male rats. GPR54 antagonist‑1 can be used for the study of prostate cancer and endometriosis.
    GPR54 antagonist-1
  • HY-182447
    Contragestazol 69095-83-6
    Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G0/G1 phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals.
    Contragestazol